Adma Biologics Inc. (NASDAQ:ADMA) shares fell 0.6% during mid-day trading on Wednesday . The stock traded as low as $6.89 and last traded at $7.08, with a volume of 89,646 shares. The stock had previously closed at $7.12.

Several brokerages have recently issued reports on ADMA. Maxim Group reduced their price objective on Adma Biologics from $24.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, July 25th. Raymond James Financial Inc. cut Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st.

The stock has a 50-day moving average of $5.89 and a 200 day moving average of $6.56. The stock’s market capitalization is $91.23 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/adma-biologics-inc-adma-trading-down-0-6.html

Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.11. Adma Biologics had a negative net margin of 231.85% and a negative return on equity of 1,293.57%. On average, equities analysts anticipate that Adma Biologics Inc. will post ($1.76) EPS for the current year.

A number of large investors have recently modified their holdings of the company. Iguana Healthcare Management LLC bought a new stake in shares of Adma Biologics during the second quarter valued at $744,000. Sabby Management LLC bought a new stake in shares of Adma Biologics during the second quarter valued at $595,000. Guggenheim Capital LLC increased its stake in shares of Adma Biologics by 36.3% in the second quarter. Guggenheim Capital LLC now owns 29,747 shares of the company’s stock valued at $177,000 after buying an additional 7,929 shares during the period. UBS Oconnor LLC increased its stake in shares of Adma Biologics by 111.3% in the second quarter. UBS Oconnor LLC now owns 71,174 shares of the company’s stock valued at $423,000 after buying an additional 37,497 shares during the period. Finally, Spark Investment Management LLC increased its stake in shares of Adma Biologics by 126.8% in the second quarter. Spark Investment Management LLC now owns 31,300 shares of the company’s stock valued at $186,000 after buying an additional 17,500 shares during the period. Institutional investors own 73.91% of the company’s stock.

Adma Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

5 Day Chart for NASDAQ:ADMA

Receive News & Ratings for Adma Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adma Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.